You are here
How I Manage: Chronic Myeloid Leukemia by Jerald Radich, MD
" The tyrosine kinase inhibitors (TKIs) have irrevocably changed the care of chronic myeloid leukemia (CML) patients, dramatically changing the natural history of this disease.1-4 With multiple TKIs available, we now have an “embarrassment of riches” in treatment options. Below are some common questions and clinically relevant answers regarding treatment.
1-4 With multiple TKIs available, we now have an “embarrassment of riches” in treatment options. Below are some common questions and clinically relevant answers regarding treatment.
The choices are imatinib (Gleevec, Novartis) and the more potent second-generation TKIs nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, Bristol-Myers Squibb). Here are some basic considerations for selecting therapy:........"